ART-400

ART-400 is a preclinical-stage small molecule anticancer immunotherapy being developed by Arum Therapeutics. The program focuses on the modulation of immune checkpoint molecules and cytokines to counteract the immunosuppressive tumor microenvironment and enhance the body's natural immune response against malignant cells. As of 2024, ART-400 is in the lead optimization phase, with the developer preparing for transition into Phase 1 clinical trials. By utilizing a small molecule modality, ART-400 aims to provide a differentiated therapeutic profile compared to existing antibody-based immunotherapies, potentially offering improved tumor penetration and the possibility of oral administration.